If you’ve ever wondered how some people seem to erase their frown lines overnight, there’s a good chance they’re using something called a neuromodulator. Or the more common name for the entire category, Botox. And a new name in this category that is catching attention is Jeveau.
Jeuveau (pronounced “Jū-vō”) is a wrinkle-fighting injectable that’s making waves for one simple reason: it was made specifically for aesthetics. Although Botox and newer generation injectables in the category, like Dysport and Xeomin, are now widely used in med spas and offices for cosmetic reasons, that was not their original intended use. And this is where Jeuveau stands out because it was!
And why should you care, as you are discussing with your medical provider and weighing your options, because it was designed to be more effective in the areas that cosmetic consumers care the most about. Whether you’re curious about smoothing out glabellar lines, also known as elevens (those vertical lines between your eyebrows), or looking for a more affordable alternative to Botox®, here’s what you need to know.
What Is Jeuveau?
Jeuveau is an injectable treatment made from botulinum toxin type A, the same kind of ingredient used in well-known products like Botox, Dysport, and Xeomin. But here’s the twist: Jeuveau is the first and only product developed purely for cosmetic use, no medical treatments, just beauty. If you are still trying to figure out why that matters, keep reading.
It was approved by the U.S. Food and Drug Administration (FDA) in 2019 to temporarily reduce moderate to severe frown lines. That means it relaxes the muscles that cause wrinkles when you frown, leaving your skin smoother and more youthful-looking.
Where Did Jeuveau Come From?
Jeuveau was developed in South Korea (originally known as Nabota) and is sold in the U.S. by a company called Evolus. In other parts of the world, it’s also known as Nuceiva™.
What sets Jeuveau apart is that it’s made using a high-purity process called “Hi-Pure,” which helps ensure the product has fewer inactive proteins. This can reduce the risk of your body developing resistance over time, a rare but possible issue with repeat neuromodulator use. And for those who are interested in starting early with the newer trend of “preventive Botox” this could be an attractive way to avoid potential issues as you get older and continue use.
How Jeuveau Works (in Simple Terms)
Your facial muscles move every time you smile, frown, or squint. Over time, those movements cause fine lines and wrinkles. Jeuveau works by temporarily stopping the signals between nerves and muscles, so the muscles stay relaxed. This function is similar to neuropeptides like Argireline, just much more effective and longer lasting. When those muscles don’t contract as strongly, the skin above them doesn’t wrinkle as much. And particularly if you are interested in using a neuromodulator for preventative reasons, this means you are less likely to develop deep wrinkles at common expression line locations over time.
The effect kicks in quickly, some people see smoother skin as early as 2–3 days after treatment, and it typically lasts 3 to 4 months.
What Makes Jeuveau Different?
There are a few key reasons Jeuveau stands out:
1. Aesthetics-Only Focus
Unlike Botox, which is also used for migraines and other medical issues, Jeuveau is only for cosmetic purposes. That focused approach means it’s often priced about 20–25% lower than Botox for the same treatment areas.
2. Clinically Proven Results
In clinical trials, 87% of patients treated with Jeuveau saw noticeable improvements in their frown lines within 30 days, which was the same as Botox users ~83%.
3. Comparable Safety
Side effects are rare and similar to other wrinkle-relaxing treatments. The most common issues include mild headache or slight eyelid drooping, which usually go away on their own.
Where Can Jeuveau Be Used?
Though Jeuveau is officially approved for treating glabellar lines (the “11” lines between the eyebrows), doctors often use it “off-label” for other common expression line areas like:
- Crow’s feet (wrinkles around the eyes)
- Forehead lines
- Eyebrow lifting
In a head-to-head comparison, Jeuveau performed just as well as Botox in treating crow’s feet, with over 65% of patients seeing major improvements.
So Who Is Jeuveau Best For…
The short answer? Almost anyone who wants to soften facial wrinkles. But interestingly, younger users especially Millennials responded even better in clinical studies. Over 97% of patients aged 20–39 saw results, compared to 85% in older age groups.
That’s good news for people interested in preventative skincare, starting early might help keep wrinkles from forming in the first place.
How Long Do Results Last?
- Standard Treatment (20 units): Most people see results last 3 to 4 months
- Higher Dose (40 units, off-label): In some studies, results lasted up to 6 months, without added safety risks
Like other neuromodulators, you’ll likely need maintenance injections a few times a year to keep up the results.
Is Jeuveau Safe?
Yes. Across thousands of treatments, Jeuveau has shown a very low rate of side effects, with no serious safety concerns reported in clinical studies. In fact, Jeuveau had nearly the same safety profile as Botox in direct comparison clinical trials.
The Bottom Line: Why Jeuveau Matters
If you’re looking for a wrinkle-relaxing treatment that delivers fast, natural-looking results, without the price tag of some older brands, Jeuveau is worth considering. Backed by clinical research and built for beauty-first users, Jeuveau offers a modern, focused approach to anti-aging that works across age groups and skin types.
And with FDA approval, strong safety data, and growing popularity in the aesthetics world, Jeuveau is quickly earning its place in skincare routines everywhere. If you are seriously considering trying out Jeuveau you should consult a medical professional and see if it is a fit for you.
References
Beer, K.R., Shamban, A.T., Avelar, R.L., Gross, J.E., & Jonker, A. (2019). Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery, 45(12), 1381-1393. DOI: 10.1097/DSS.0000000000001903
Cheon, H.I., Jung, N., Won, C.H., Kim, B.J., & Lee, Y.W. (2019). Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow’s feet: a phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery, 45(12), 1610-1619. DOI: 10.1097/DSS.0000000000001920
Rzany, B.J., Ascher, B., Avelar, R.L., et al. (2020). A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase 3, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthetic Surgery Journal, 40(4), 413-429. DOI: 10.1093/asj/sjz110
Gadarowski, M.B., Ghamrawi, R., Taylor, S.L., & Feldman, S.R. (2021). PrabotulinumtoxinA-xvfs for the treatment of moderate-to-severe glabellar lines: a review of phase II and III clinical trials. Annals of Pharmacotherapy, 55(3), 279-287. DOI: 10.1177/1060028020943527
Avelar, R.L. (2024). Post hoc analysis comparing the safety and efficacy of prabotulinumtoxinA in millennials and nonmillennials with moderate to severe glabellar lines. Dermatologic Surgery, 50(9 Suppl), S42–S47. DOI: 10.1097/DSS.0000000000004249
Lemdani, M.S., Honig, S.E., Habarth-Morales, T.E., et al. (2025). Comparison of botulinum toxin A formulations for glabellar strain treatment in women: a double-blind randomized clinical trial. JAMA Dermatology, 161(7), 723-730. DOI: 10.1001/jamadermatol.2025.1335
Jung, B.K., Park, H., Cheon, Y.W., et al. (2023). Clinical investigation of botulinum toxin (prabotulinumtoxin A) for bruxism related to masseter muscle hypertrophy: a prospective study. Journal of Cranio-Maxillofacial Surgery, 51(5), 332-337. DOI: 10.1016/j.jcms.2023.05.005
Fagien, S., Avelar, R.L., Cox, S.E., Joseph, J.H., Kaufman-Janette, J., & Marcus, K.A. (2024). Safety and duration of effect of 40-unit prabotulinumtoxinA-xvfs for the treatment of moderate to severe glabellar lines in adult patients: a phase II, multicenter, randomized, double-blind, active-controlled trial. Aesthetic Surgery Journal, 44(9), 987-1000. DOI: 10.1093/asj/sjae051
Clifton, M. (2023). PrabotulinumtoxinA-xvfs (Jeuveau, Evolus) for the temporary treatment of glabellar lines: what does this toxin bring to the table? The Dermatology Digest.
European Medicines Agency. (2019). Nuceiva (botulinum toxin type A) – EPAR Product Information. EMA/249428/2019. (Available at EMA website).
